|
|
|

Come learn about our upcoming collaboration system for labs and researchers in the field of adult stem cells - CLICK HERE
|
The Adult Stem Cell Research (ASCR) Network is an Internet-based project of The Cell Therapy Foundation designed to be a well-maintained and reliable source of information for the public regarding adult stem cell research, as well as to be a community of practice and collaboration among fellow researchers. ASCR publishes the latest scientific news in the adult stem cell arena, identifies the leading researchers in the field, and locates key clinical trials; as well as connects the global community of adult stem cell researchers with one another.
Getting Started...
Available Clinical Trials
|

|
|
|
Entest BioMedical Announces Creation of Proprietary Adult Stem Cell Lines To Serve as Platform for Screening of Regenerative Photoceuticals |
|
|
|
March 08, 2010: 08:00 AM ET
Entest BioMedical Inc. (OTCBB: ENTB) announced today the creation of 3 bone marrow derived stem cell lines useful for optimizing laser intensities and wavelengths in laser enhanced stem cell therapy. A stem cell line is a defined cell population that is derived from a single cell and has the capability to replicate for long periods of time in vitro. Proprietary stem cell lines are commonly licensed for various applications ranging from research to product development.
The Company believes the development of these stem cell lines will assist in the progress of its stem cell therapy for COPD treatment.
|
|
Read more...
|
|
Theory of single stem cell for blood components challenged |
|
|
Glenna Picton 713-798-7973
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
RSS icon HOUSTON -- (March 5, 2010) -- Components of the blood or hematopoietic system derive from stem cell subtypes rather than one single stem cell that gives rise to all the different kinds of blood cells equally, said scientists from Baylor College of Medicine in a report that appears in the current issue of the journal Cell Stem Cell.
"While previous reports in journals have hinted at the possibility of stem cell subtypes, this study represents the clearest data to show that is true," said Dr. Margaret Goodell, director of the Stem Cells and Regenerative Medicine (STaR) Center at BCM. "From a scientific point of view, it's making us re-evaluate the view of the stem cells that come from adults. It challenges the dogma that there is one type of stem cell."
|
|
Read more...
|
|
Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells Promises broad clinical benefits, from bone marrow transplantation to therapies for heart, brain, skin and lungs |
|
|
Contact: Andrew Klein
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
212-821-0560 New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
NEW YORK (March 4, 2010) -- In a leap toward making stem cell therapy widely available, researchers at the Ansary Stem Cell Institute at Weill Cornell Medical College have discovered that endothelial cells, the most basic building blocks of the vascular system, produce growth factors that can grow copious amounts of adult stem cells and their progeny over the course of weeks. Until now, adult stem cell cultures would die within four or five days despite best efforts to grow them.
|
|
Read more...
|
|
NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant |
|
|
|
NEW YORK, March 4 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR). Under terms of the SRA, NeoStem will have the first option to license discoveries stemming from the project.
|
|
Read more...
|
|
|
|
|
<< Start < Prev 1 2 3 Next > End >>
|
|
Page 1 of 3 |
|
 |
*Designates sites with available clinical trials. - *Minneapolis Heart Institute Foundation, Minneapolis, MN
- *Stem Cell Center at Texas Heart Institute, Houston, TX
- *Indiana Center for Vascular Biology and Medicine, Laboratories, Indianapolis, IN
- *Feinberg Cardiovascular Research Institute - Northwestern University, Chicago, IL
- Yoder Laboratory - Indianapolis, IN
- Stem Cell Research Center - Taipei, Taiwan
- Adult Stem Cell Research Ctr, Seoul National University, Seoul, South Korea
- Wake Forest Institute of Regenerative Medicine, Winston-Salem, NC
- Division of Clinical Immunology and Transfusional Medicine, Stockholm, Sweden
- Stem Cell Research Center - Pittsburgh, PA
- Adipose Stem Cell Center, University of Pittsburgh, Pittsburgh, PA
- Adipose Tissue Plasticity
- Stem Cell Biology Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA
- Interdisciplinary Stem Cell Institute/UM Med, Miami, FL
- Penn Lab - Cleveland Clinic, Cleveland, OH
- Kolonin Lab - Centre for Stem Cell Research, Houston, TX
- Naviaux Lab - The Mitochondrial and Metabolic Disease Center San Diego, CA
- Excellion Biomedical Services, Petropolis, Rio de Janeiro
- Center for Cardiovascular Cell Therapy, Louisville, KY
- RhinoCyte™, Inc., Louisville, KY
- The Cardiovascular Research Institute, Washington, DC
- Research & Development Unit - National Heart Centre, Singapore
- Simari Lab - Mayo Clinic, Rochester, MN
- Skeletal Tissue Engineering Group Amsterdam
- Stem Cell Biology and Cell Therapy Laboratory, Philadelphia, PA
- LIT - Laboratory of Transplantation Immunology
- Scandurro Research Laboratory - New Orleans, LA
- Laboratory for Stem Cell Injury - Charleston, SC
- Institute of Cell and Molecular Science - London, England
- Adult Stem Cell Laboratory - Seoul, South Korea
|
|
|